First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Buy” from Brokerages

First Tracks Biotherapeutics (NASDAQ:TRAX) has received an average rating of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $39.4286.

Several analysts have recently weighed in on TRAX shares. UBS Group started coverage on shares of First Tracks Biotherapeutics in a research note on Tuesday, April 21st. They set a “buy” rating and a $45.00 price target for the company. Wedbush assumed coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $30.00 price target for the company. Leerink Partners assumed coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $46.00 price objective for the company. HC Wainwright assumed coverage on shares of First Tracks Biotherapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 price objective for the company.

First Tracks Biotherapeutics Trading Up 2.5%

First Tracks Biotherapeutics stock opened at $17.18 on Friday. First Tracks Biotherapeutics has a fifty-two week low of $14.79 and a fifty-two week high of $26.80.